Using Gadoxetate MRI to improve detection of liver metastases in colorectal cancer
A Prospective Study Evaluating Diagnostic Accuracy, Outcome, and Economic Impact of Abbreviated Gadoxetate-enhanced MRI of the Liver in Patients With Metastatic Colorectal Carcinoma
This study is testing if a special type of MRI can better identify liver tumors in patients with colorectal cancer to help guide their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other |
| Locations | 2 sites (London, Ontario and 1 other locations) |
| Trial ID | NCT05314400 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of Gadoxetate-enhanced MRI in detecting liver metastases in patients diagnosed with colorectal cancer. Patients who have previously undergone imaging that shows liver lesions will receive either a full or abbreviated Gadoxetate-enhanced MRI to assess the nature of these lesions. The study aims to determine if this imaging technique can provide better characterization of liver tumors, which is crucial for surgical planning and treatment decisions. Conducted at London Health Sciences Centre, the trial focuses on improving the accuracy of liver metastasis detection to enhance patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a biopsy-proven diagnosis of colorectal cancer and prior imaging indicating liver lesions.
Not a fit: Patients with diffuse liver metastases that are definitively unresectable or those with severe liver dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate detection and characterization of liver metastases, improving surgical outcomes for colorectal cancer patients.
How similar studies have performed: Other studies have shown promising results with similar imaging approaches, suggesting potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female, 18 years of age or older * Diagnosis of colorectal cancer, biopsy proven * Prior imaging showing liver lesions that may be metastases * Provision of signed and dated informed consent form * Willingness to comply with study procedures and availability for the duration of the study * Able to tolerate MRI required by protocol Exclusion Criteria: * Presence of implanted medical device or metallic object that is MR incompatible * Baseline eGFR of \< 30 mL/min/1.73 m2 * Severe claustrophobia not relieved by oral anxiolytics * Documented severe allergic-like reaction gadolinium-based contrast agent * Weight greater than allowable on MRI table * Pregnancy * Diffuse liver metastases, i.e. definitively unresectable * Severe liver dysfunction, ALBI grade 3
Where this trial is running
London, Ontario and 1 other locations
- St. Joseph's Healthcare — London, Ontario, Canada (Recruiting)
- London Health Sciences Centre — London, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Harry Marshall, MD/PhD
- Email: harry.marshall@lhsc.on.ca
- Phone: 519-685-8500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.